In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts-Medco Deal Showcases New Post-Health Reform Reality

Executive Summary

Express Scripts' merger agreement with Medco Health Solutions to form a mega-pharmacy benefits manager fits the new realities of the post-health care reform world. Together, the two PBMs managed more than 1.7 billion prescription claims for approximately 135 million individuals in 2010; thus, the tie-up, which was announced July 21, creates an entity that dominates the PBM space by a wide margin, with CVS Caremark the only other major competitor.

You may also be interested in...



Aetna Internal PBM No Longer In Play With CVS Caremark Contract

Aetna's new 12-year contract to merge some of its internal pharmacy benefit management operations with CVS Caremark appears to take Aetna's in-house PBM out of play as a potential acquisition target

Medco: Market Multiplier for Personalized Medicine

Medco is developing data that could accelerate the adoption of personalized medicine--as a way to make itself more relevant to customers and the lives they represent. Armed with infrastructure from its mail pharmacy business and access to medical information on large groups of people, it is financing and conducting studies to show the value of pharmacogenomic tests in improving clinical outcomes. By so doing, it could become an incredible enabler of companies pursuing personalized medicine.

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel